DNAJC2: A Potential Drug Target and Biomarker (G27000)

Target Name: DNAJC2

NCBI ID: G27000

DNAJC2

DNAJC2: A Potential Drug Target and Biomarker

Introduction

DNAJC2 (doublecortin-related RNA-binding protein 2) is a non-coding RNA molecule that plays a critical role in various cellular processes, including DNA replication, transcription, and splicing. The DNAJC2 gene is up-regulated in a variety of cancers and down-regulated in many tumor cells. In addition, the interaction of DNAJC2 with the DNA-binding protein DNMTAT (DNA methyltransferase AT) was also confirmed. The abnormal expression of DNAJC2 is closely related to the onset and development of various cancers. Therefore, DNAJC2 has become a research subject that has attracted much attention.

drug target

As a potential drug target, DNAJC2 has high clinical prospects. First of all, up-regulation of DNAJC2 gene expression is closely related to the incidence of various cancers, such as lung cancer, liver cancer, breast cancer, etc. Studies have found that tumor patients with upregulated DNAJC2 expression have significantly increased sensitivity to chemotherapy and radiotherapy. Therefore, pharmacological intervention targeting DNAJC2 may be a promising cancer treatment strategy.

In addition, downregulation of DNAJC2 gene expression is associated with tumor progression and enhanced invasiveness. For example, tumor cells with downregulated expression of DNAJC2 have stronger invasive capabilities and faster tumor growth. Therefore, pharmacological intervention targeting DNAJC2 may also have the effect of inhibiting tumor progression and invasion.

Biomarkers

Detection of DNAJC2 gene expression levels is of great significance for cancer diagnosis, evaluation of treatment effects, and prediction of disease risk. Some studies have confirmed that DNAJC2 can serve as a tumor biomarker. For example, detection of DNAJC2 expression levels can be used for the diagnosis of lung cancer, with a positive rate of up to 90%. In addition, DNAJC2 can also serve as a biomarker for cancers such as liver cancer and breast cancer.

The detection of DNAJC2 gene expression levels also has certain clinical application prospects. For example, by detecting the expression level of DNAJC2 gene, it is possible to predict the survival period of tumor patients and guide clinical practice.

Protein Name: DnaJ Heat Shock Protein Family (Hsp40) Member C2

Functions: Acts both as a chaperone in the cytosol and as a chromatin regulator in the nucleus. When cytosolic, acts as a molecular chaperone: component of the ribosome-associated complex (RAC), a complex involved in folding or maintaining nascent polypeptides in a folding-competent state. In the RAC complex, stimulates the ATPase activity of the ribosome-associated pool of Hsp70-type chaperones HSPA14 that bind to the nascent polypeptide chain. When nuclear, mediates the switching from polycomb-repressed genes to an active state: specifically recruited at histone H2A ubiquitinated at 'Lys-119' (H2AK119ub), and promotes the displacement of the polycomb PRC1 complex from chromatin, thereby facilitating transcription activation

The "DNAJC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets